Vaginal atrophy & GSM assessment
Vaginal atrophy and GSM assessment and treatment
Private, assessment-led care for women experiencing menopause-related vaginal dryness, vulval burning or soreness, painful intimacy, urinary urgency, recurrent UTI-like symptoms or treatment-related tissue changes.
- CQC registered Regulated and inspected
- 4.8 / 5 From 3,500+ reviews
- Clinician-led Personalised care
What is vaginal atrophy or genitourinary syndrome of menopause?
Vaginal atrophy describes low-oestrogen changes that can make vaginal and vulval tissues drier, thinner, less elastic and more easily irritated. Genitourinary syndrome of menopause (GSM) is the broader clinical term because the same low-oestrogen changes may also affect the urethra, bladder and urinary tract.
This page owns clinically specific vaginal-atrophy and GSM assessment and treatment. The vaginal dryness page owns symptom-led dryness where the cause is not yet known, while the menopause service covers the wider hormonal picture, HRT and broader menopause symptoms.
Vaginal and vulval change
Dryness, burning, soreness, irritation, reduced lubrication, splitting, tissue fragility or pain with intimacy may form part of GSM.
Urinary symptoms
Urgency, frequency, bladder sensitivity, burning when urine contacts fragile tissue and recurrent UTI-like symptoms may occur alongside vaginal symptoms.
Daily life and wellbeing
Symptoms may affect clothing comfort, exercise, sleep, confidence, sexual comfort and relationships. These effects are clinically relevant, not merely cosmetic.
Why the distinction matters
Dryness is a symptom. GSM is a clinical syndrome.
Not every case of dryness is GSM, and not every urinary symptom is caused by menopause. Assessment helps separate low-oestrogen tissue change from infection, vulval skin disease, pelvic-floor pain, urinary disease or another cause.
GSM can affect more than vaginal lubrication.
Symptoms may occur alone or together. Their presence does not confirm GSM, but the pattern helps guide assessment and rule out other causes.
Dryness, tightness or fragility
Tissue may feel dry, less elastic, raw, easily irritated or more vulnerable to splitting and friction.
Burning, stinging or soreness
Symptoms may be present during the day, after washing, with clothing, after urination or during a flare.
Painful or avoided intimacy
Reduced lubrication, tissue sensitivity or splitting may make penetration uncomfortable or create fear of pain.
Urgency or frequency
Some women notice stronger urgency, more frequent urination, bladder sensitivity or waking at night.
Recurrent UTI-like symptoms
Burning, cystitis-like flares or repeated urinary symptoms need infection testing where indicated rather than automatic attribution to GSM.
Symptoms that do not fit neatly
Discharge, odour, bleeding, new skin changes, severe pain or one-sided symptoms may indicate another condition and require review.
When GSM-type symptoms need assessment before treatment
GSM is common, but bleeding, infection, lesions, significant urinary symptoms and cancer-treatment history should not be managed by assuming every symptom is low-oestrogen change.
The safest route is to clarify what needs testing, what needs referral, and which established or non-hormonal options may be appropriate before considering a procedure.
Do not assume these symptoms are GSM
Postmenopausal or unexplained bleeding
Any new postmenopausal bleeding, unexplained bleeding or persistent post-coital bleeding requires assessment before elective GSM treatment.
New lump, ulcer, lesion or skin change
A new lump, persistent ulcer, thickened area, colour change or non-healing lesion needs appropriate clinical review.
Infection or severe inflammation
Unusual discharge, odour, fever, severe pelvic pain, active thrush, BV, STI, PID, UTI or herpes should be assessed and treated first.
Blood in urine or difficulty emptying
Visible blood in urine, recurrent confirmed infections, retention, kidney pain or sudden severe urinary change requires medical review.
Cancer history and anti-oestrogen treatment
A history of hormone-sensitive cancer, pelvic radiotherapy, ovarian suppression or current anti-oestrogen therapy changes how local hormonal and procedural options are considered.
No blanket approval or refusal
Suitability depends on cancer type, current treatment, symptoms and specialist advice. The clinician may recommend liaison with your GP, menopause specialist or oncology team.
Non-hormonal options still need assessment
Moisturisers, lubricants and selected non-hormonal approaches may be discussed, but “non-hormonal” does not automatically mean suitable or evidence-equivalent.
Radiotherapy and tissue healing
Previous pelvic radiotherapy can alter tissue response and healing, so procedures or injectables require additional caution and may not be appropriate.
Injectable-treatment cautions
Bleeding disorders, anticoagulants, allergy, active infection and healing risk may alter suitability for PRP, HA, filler or other injectable approaches.
Energy-based-treatment cautions
Pregnancy, infection, unexplained bleeding, recent surgery, active inflammation, radiotherapy history and some implanted devices may change laser or RF suitability.
Alternatives remain part of consent
A procedure is not automatic. Established local care, non-hormonal symptom support, infection or skin treatment, pelvic-floor care, referral or watchful review may be more appropriate.
How vaginal atrophy and GSM are assessed
Assessment brings the vaginal, vulval, urinary, menopause and medical-history pieces together. It also identifies symptoms that are better explained by infection, a vulval condition, pelvic-floor pain or urinary disease.
The process is paced around your comfort. Examination or testing is recommended only where it is clinically useful and proceeds only with consent.
Symptoms and timing
We review dryness, burning, soreness, itching, splitting, reduced lubrication, painful intimacy, urinary urgency, frequency and recurrent UTI-like symptoms, including when they began and what worsens them.
Menopause and medical context
Natural or surgical menopause, HRT or local-oestrogen use, medication, cancer treatment, anti-oestrogen therapy, pelvic radiotherapy and previous procedures all influence the pathway.
Sensitive examination where appropriate
With consent, examination may help assess tissue fragility, dryness, narrowing, inflammation, discharge, vulval skin changes, tenderness or pelvic-floor guarding.
Testing or referral where indicated
Where symptoms suggest infection, bleeding, urinary disease or a dermatological concern, the clinician may recommend appropriate testing, GP review or specialist referral rather than proceeding directly to treatment.
Differential and owner routing
We consider whether the dominant issue is GSM, symptom-led dryness, menopause management, vulval skin disease, dyspareunia, pelvic-floor dysfunction or a urinary problem.
Plan, consent and review
Established care, non-hormonal support, oncology-aware choices, procedural options, risks, costs and expected review are explained before you decide whether to proceed.
You do not need to self-diagnose
The purpose of assessment is to make the safest next step clearer
Many women have overlapping symptoms. A structured review clarifies what is likely GSM, what needs checking, which treatment tier fits, and how progress should be reviewed.
Who may benefit from vaginal atrophy or GSM assessment?
This pathway is designed for clinically menopause-related vaginal, vulval and urinary symptoms, while still checking for conditions that need a different route.
Natural menopause or perimenopause
Dryness, soreness, burning, painful intimacy, urgency or recurrent UTI-like symptoms appearing around the menopause transition.
Surgical or treatment-induced menopause
Symptoms after ovarian surgery, ovarian suppression, chemotherapy, pelvic radiotherapy or other treatment causing abrupt hormonal change.
Persistent symptoms despite self-care
Moisturisers or lubricants provide incomplete relief, symptoms recur, or urinary and vulval symptoms suggest a broader GSM pattern.
Urinary symptoms alongside tissue change
Urgency, frequency, bladder sensitivity or recurrent UTI-like symptoms occurring with dryness, burning or soreness.
Cancer-treatment or anti-oestrogen context
You need an oncology-aware discussion of local hormonal and non-hormonal options rather than generic advice.
Low-oestrogen symptoms outside menopause
Breastfeeding or postpartum low-oestrogen symptoms are considered as a differential, but may be better routed through the symptom-led dryness pathway rather than treated as menopause-specific GSM.
GSM is the condition-specific pathway, not a synonym for every case of dryness.
Formal GSM assessment brings together low-oestrogen vaginal, vulval and urinary symptoms. Other pages remain the primary owners when dryness is unexplained, broader menopause care is needed, or another condition is dominant.
Vaginal dryness
Symptom-led assessment when the cause is not yet known.
Menopause
Broader hormone symptoms, HRT and whole-person menopause care.
Painful sex
For pain where pelvic-floor, vulval, scarring or deeper causes may be dominant.
Vulval skin disease
For itching, fissures, white patches or suspected inflammatory skin change.
Vaginal atrophy and GSM treatment pathways
Treatment should begin with established symptom support and medical options where appropriate. Procedures sit later in the pathway and should not be presented as routine substitutes for first-line care.
The clinician explains what is directly provided, what may be prescribed or coordinated, what is evidence-limited, and what alternatives remain available.
Vaginal moisturisers, lubricants and vulval care
Regular moisturisers can support baseline comfort; lubricants reduce friction during intimacy; simple vulval care may reduce avoidable irritation. These measures may be used alone or alongside medical treatment.
Local vaginal oestrogen where suitable
Local vaginal oestrogen is an established treatment for menopausal GSM. A clinician will confirm whether it is appropriate and, where within scope, prescribe or coordinate treatment. Cancer history and anti-oestrogen therapy require individual review.
Wider hormone and prescription choices
Where broader menopause symptoms are present, systemic HRT or other prescription choices may need discussion through the menopause pathway. Local GSM symptoms may still require specific local management even when systemic treatment is used.
When hormone-sensitive cancer history changes the plan
Non-hormonal symptom support may be prioritised while local hormonal treatment is considered with appropriate specialist input. No procedure is automatically safer simply because it is non-hormonal.
HA hydration, Nu-V CO₂ laser, RF, PRP and external support
These options may be discussed only when the symptom objective, tissue findings and safety profile are suitable. They are not routine first-line treatment, are not guaranteed, and do not replace treatment of infection, skin disease or another diagnosis.
Exosomes and regenerative combinations
Exosomes and some regenerative combinations have a developing evidence and regulatory context. They should be described transparently, with uncertainty, alternatives and the absence of guaranteed outcomes made explicit.
Realistic goals
Treatment aims to improve symptoms and tissue comfort, not promise a permanent cure.
GSM is often long term. Maintenance, reassessment and adjustment may be needed as menopause, medication, health and tissue response change.
Your enquiry is private, simple and low-pressure.
The first step clarifies whether your symptoms fit GSM, whether a doctor-led consultation is recommended, and whether investigation, established treatment, oncology liaison or a later procedural discussion is the appropriate route.
Request a confidential consultationWe contact you discreetly
You can begin without giving a detailed intimate history online. The team confirms the most suitable consultation route.
You describe the symptom pattern
Tell us what changed, when it began, whether urinary symptoms are present and what treatments or products you have already tried.
We guide the clinical next step
This may be advice, doctor review, examination, testing or referral, established treatment, or later assessment for a selected procedure.
Consent and comfort
Nothing happens without your consent.
If an intimate examination is recommended, the clinician explains why, what it involves and what alternatives may exist. A chaperone can be provided.
You can ask questions, pause, decline, seek a second opinion or take time before deciding about treatment.
The cost of starting is separate from the cost of treatment.
A free nurse telephone consultation is available as an initial conversation. We generally recommend a paid doctor telephone consultation when diagnosis, prescribing, urinary symptoms, cancer history or procedural suitability need medical review.
Where an in-person assessment is advised, the fee and appointment purpose are confirmed before booking. No treatment should be assumed before the clinical review.
Initial conversation
Free nurse telephone consultation
A confidential first conversation to understand your concerns and whether a clinical appointment is the appropriate next step.
No treatment decision required
Recommended route
Paid doctor consultation
Recommended for clinical diagnosis, prescribing, oncology-aware decision-making, complex urinary symptoms or procedure suitability.
View consultation and pricing pathwayWhere needed
Face-to-face clinical assessment
Recommended where examination, tissue assessment or a procedure-specific review is clinically useful. The purpose and fee are confirmed first.
Consent-led and paced around you
Clinical choice
You can stop at advice.
If treatment is unnecessary, unsuitable or outside WHC's role, the clinician will explain the more appropriate next step.
Request consultationConsultation pathway
Assessment and established care come before procedure selection
The first decision is whether symptoms fit GSM and whether local medical, non-hormonal, oncology-aware or referral care is needed. Procedure fees apply only when a specific option is clinically appropriate.
Indicative procedure prices
Selected treatment prices from
These fees are relevant only after suitability is confirmed. Prescription, conservative and referral pathways may have different or separate costs.
Nu-V / CO₂ laser
From £599
Nurse-led; doctor-led pricing differs.
HA hydration
From £795
Single treatment where suitable.
RF
From £699
Course options may apply.
PRP
From £1,110
Standalone or course pricing.
Vaginal atrophy and GSM treatment prices
Established local treatment, moisturisers, lubricants and appropriate medical review come before procedure selection. The fees below relate only to clinic-based options that remain suitable after assessment.
Prices below are indicative and subject to change. Final recommendations depend on consultation, assessment findings, symptoms, medical history, suitability and goals. Please also refer to our latest pricing page.
Before choosing treatment
Treatment choice depends on safety, symptoms and suitability
If you have unexplained bleeding, active infection, suspected malignancy, significant cancer-treatment history or pelvic radiotherapy history, treatment choice may need further medical review first.
Nu-V / fractional CO₂ laser
Nu-V laser may be discussed for selected GSM / tissue-change symptoms after clinical assessment and evidence counselling.
Nurse-led single session
£599
Indicative single-session price.
Doctor-led single session
£799
Indicative single-session price.
Nurse-led course of 3
£1,200
Indicative course pricing.
Doctor-led course of 3
£1,800
Indicative course pricing.
PRP / platelet-rich plasma
£1,110
Standalone session
£2,985
Course of 3
Hyaluronic acid hydration booster
£795
Single session
£1,400
Course of 2
Radiofrequency treatment
£699
Single session
£2,300
Course of 4
Labia majora filler and vulval tightening
Exosomes and combination package
Prices last reviewed July 2026 and remain indicative. They may be updated. Final treatment planning and suitability are confirmed after consultation and assessment. Please refer to the latest WHC pricing page for current pricing.
Reviews
Experiences shared by women like you
Real feedback from women who felt listened to, supported and cared for throughout their journey.
Fantastic service by everyone. I could talk openly without feeling embarrassed, and everything was explained clearly. The team made me feel so comfortable and at ease.
Finally, a place that explains everything fully. The staff put my mind at ease and I felt listened to, understood, and given sound advice.
Katy went above and beyond making me feel comfortable and making sure I understood everything that was happening and what to expect. Very nice and clean facilities.
GSM often affects more than one part of life
These are the kinds of symptoms and concerns women commonly raise in consultation.
“
It feels dry, sore or burning even when I am not sexually active.
“
Intimacy has become painful, so I have started avoiding it.
“
I keep getting urgency or UTI-like symptoms and I did not realise GSM could be involved.
“
I want to understand hormonal and non-hormonal options clearly before deciding.
These are representative concerns commonly discussed in consultations, not individual verified patient reviews.
Helpful videos on GSM, vaginal atrophy and treatment choices
These videos support the page by explaining related symptoms, treatment choices and what to consider before deciding on a pathway.
Can untreated vaginal atrophy cause prolapse? | WHC Clinical FAQ
What are the common symptoms of vaginal atrophy (GSM)? | WHC Clinical FAQ
What is the difference between vaginal atrophy and vaginal dryness? | WHC Clinical FAQ
What is vaginal atrophy and how does it cause dryness? | WHC Clinical FAQ
Can vaginal atrophy cause chronic pelvic pain? | WHC Clinical FAQ
Frequently asked questions about vaginal atrophy and GSM treatment
These are some of the most common questions women ask when dryness, burning, painful intimacy or urinary symptoms may be linked to GSM.
We answer them clearly while keeping treatment claims realistic and evidence-aware.
Is vaginal atrophy the same as vaginal dryness?
Can urinary symptoms really be linked to GSM?
What is the most established treatment?
Is laser proven for GSM?
Can I choose a non-hormonal plan?
Can I use vaginal oestrogen after breast cancer?
How quickly will symptoms improve?
Is GSM treatment permanent?
Can treatments be combined?
What if moisturisers have not worked?
When should I use the vaginal dryness page instead of this GSM page?
Will GSM need ongoing maintenance?
Still unsure?
Have a question that is not covered here?
GSM can feel confusing because symptoms can involve both vaginal and urinary changes. A confidential assessment can help identify the safest and most relevant pathway.
Practical self-care for vaginal atrophy and GSM symptoms
Self-care can support comfort, reduce irritation and help you understand your symptom pattern. It does not replace medical assessment, especially if symptoms are persistent, worsening or include bleeding, infection signs or new skin changes.
The most useful routine is usually regular, gentle and symptom-led rather than relying on one product only when symptoms flare.
Use vaginal moisturisers regularly
Vaginal moisturisers are designed for baseline tissue comfort. They are different from lubricants and are usually used regularly rather than only during intimacy.
Use a suitable moisturiser consistently, often several times per week depending on the product and symptoms.
Stop any product that stings, burns or worsens irritation and seek advice.
If symptoms persist despite regular use, assessment can help decide whether step-up care is needed.
Use lubricant before friction starts
Lubricants reduce friction during intimacy. They do not treat the underlying tissue change, but they can reduce irritation and help prevent pain cycles.
Use lubricant generously and early, not only once discomfort has started.
Avoid fragranced, warming, tingling or strongly perfumed products if tissue is sensitive.
Pain with intimacy should not be pushed through. Ongoing pain needs review.
Avoid common irritants
GSM tissue can be more reactive. Removing irritants can reduce burning, stinging and flare-ups.
Avoid douching, perfumed washes, bubble baths and harsh soaps around the vulva.
Choose gentle cleansing and avoid over-washing, which can worsen dryness and irritation.
If symptoms are one-sided, severe, persistent or associated with skin changes, seek medical review.
Track urinary and flare patterns
Urinary urgency, burning and recurrent UTI-like symptoms may be linked to GSM, infection, bladder sensitivity or a combination.
Note whether symptoms are linked to intimacy, exercise, urine contact, products, dehydration or confirmed infection.
If you are repeatedly treated for UTIs, urine testing and GSM assessment can both be useful.
Blood in urine, fever, kidney pain or severe symptoms need urgent medical care.
When self-care is not enough
Persistent GSM symptoms often need a structured treatment plan
If dryness, burning, pain, urgency or recurrent UTI-like symptoms continue despite careful self-care, assessment can help decide whether prescribed local treatment, non-hormonal support or clinic-based options are appropriate.
Common myths about vaginal atrophy and GSM
GSM symptoms are often minimised or misunderstood. These myth-versus-reality cards help separate practical medical care from outdated assumptions.
The aim is not to over-medicalise every symptom. It is to make sure women are not dismissed when symptoms are persistent or affecting quality of life.
“It is just dryness.”
GSM can affect the vulva, vagina, bladder and urethra. Dryness is one symptom, but burning, pain, urinary urgency and recurrent UTI-like symptoms can also occur.
“It is just part of ageing, so nothing can be done.”
GSM is common, but it is also treatable. Options include moisturisers, lubricants, vaginal oestrogen where suitable and selected non-hormonal or clinic-based options.
“Lubricant fixes the underlying problem.”
Lubricant reduces friction during intimacy, but it does not treat tissue thinning, pH change or urinary symptoms. Many women need a broader plan.
“Only older women get GSM.”
GSM-type symptoms can also occur after surgical menopause, during breastfeeding, after cancer treatment or with anti-oestrogen medication.
“Laser or PRP are guaranteed solutions.”
Laser, PRP and other regenerative options may be discussed in selected cases, but evidence and long-term data vary. Results are not guaranteed.
“If I am aroused, dryness should not happen.”
Arousal and tissue health are related but not identical. Low-oestrogen tissues can remain dry, fragile or painful even when desire is present.
Need clarity?
GSM symptoms are valid and treatable
A careful consultation can help work out whether your symptoms are due to GSM, infection, vulval skin change, bladder issues, pelvic floor factors or a combination.
More about GSM, tissue change and treatment choices
GSM is a tissue, comfort and urinary health condition linked to low-oestrogen change. Understanding the difference between symptom relief, medical treatment and emerging procedures can help you make safer decisions.
These expandable sections give extra context for women who want to understand the science and treatment choices before consultation.
Why low oestrogen affects tissue comfort
Oestrogen helps support tissue thickness, elasticity, moisture, blood flow and the protective vaginal environment. When oestrogen falls, the tissues may become thinner, drier and more vulnerable to irritation.
This is why symptoms can include soreness, burning, splitting, painful intimacy and urinary symptoms rather than dryness alone.
Laser, RF, PRP and HA: what they are trying to do
Laser and RF
Energy-based treatments aim to create controlled tissue heating or stimulation. Evidence and long-term data vary, so counselling is essential.
PRP and HA
PRP is a biologic option using platelets. HA is a hydration-support option. Both require suitability assessment and realistic expectations.
Exosomes and investigational treatments
Why this needs careful wording
Exosomes and some regenerative approaches are evolving areas. They may be discussed only with clear explanation of uncertainty, evidence limitations, regulatory context and alternatives.
They should not be presented as established first-line GSM treatments or guaranteed outcomes.
Cancer treatment, GSM and oncology-aware care
Hormone-sensitive history
Vaginal oestrogen and other hormonal decisions may need oncology input depending on the cancer type and current treatment.
Non-hormonal discussion
Non-hormonal moisturisers, HA, PRP, RF or laser may be discussed in selected cases, but suitability still depends on tissue status and medical history.
Your rights and consent
Consent and comfort
You can pause or stop an examination or treatment at any time. A chaperone can be provided for intimate examinations.
No same-day pressure
You should never feel pressured to book a procedure on the day. A cooling-off period and second opinion are always reasonable.
Ready to ask better questions?
Understanding the options can make consultation clearer
You do not need to decide whether you need vaginal oestrogen, HA, PRP, laser or another option before booking. The consultation helps work that out.
Further support and helpful next steps
GSM can affect comfort, intimacy, urinary confidence and daily life. Symptoms are common, but they are still valid and deserve proper assessment.
These suggestions are here to support informed conversations — not to replace individual medical assessment, diagnosis or prescribing.
Useful topics to read about
Menopause and HRT care
Helpful where GSM sits within a broader menopause picture requiring hormone and whole-person review.
Vaginal dryness and painful intimacy
Helpful if dryness, burning, friction or pain during intimacy is a dominant concern.
Recurrent UTI and urinary urgency
Helpful if urinary symptoms are part of the picture and infection testing has been repeated.
Helpful if symptoms followed chemotherapy, pelvic radiotherapy, ovarian suppression or hormone-blocking medication.
What to bring to consultation
Symptom pattern
Dryness, burning, soreness, pain with intimacy, itching, urinary urgency, recurrent UTI-like symptoms, bleeding or skin changes.
Medical and treatment history
Menopause status, breastfeeding, surgery, cancer treatment, pelvic radiotherapy, HRT/local oestrogen use and medication.
What you have already tried
Moisturisers, lubricants, antibiotics, vaginal oestrogen, HA products, pelvic floor care, previous procedures or anything that helped or worsened symptoms.
Reference themes
What our page is broadly guided by
GSM can affect the vulva, vagina, urethra and bladder, not just vaginal lubrication.
Established medical options, non-hormonal comfort care and selected procedures have different evidence levels.
Bleeding, infection, cancer history and pelvic radiotherapy require extra caution before treatment planning.
Next step
You do not need to decide the treatment pathway alone
If GSM symptoms are affecting comfort, intimacy, urinary confidence or daily life, the most useful next step is a structured assessment that respects your history and preferences.
Educational only. This page is designed to support informed discussion and does not replace individual medical assessment, diagnosis, prescribing, pelvic floor physiotherapy, oncology advice or urgent care. Suitability and treatment planning depend on symptoms, history, examination findings where appropriate and the specific treatment being considered.
Clinical references and further reading
This page is informed by clinical resources relevant to GSM, urogenital atrophy, vaginal oestrogen, energy-based device guidance and selected regenerative options.
1. NICE NG23
Menopause: identification and management, including genitourinary symptoms and treatment recommendations.
View source2. NICE IPG697
Transvaginal laser therapy for urogenital atrophy: interventional procedure guidance.
View source3. FDA
Safety communication on energy-based devices marketed for vaginal rejuvenation or sexual function claims.
View source4. British Menopause Society
Educational resources and consensus information on genitourinary syndrome of menopause.
View sourceClinical governance
Reviewed by the WHC clinical team
Reviewed for vaginal atrophy/GSM terminology, established-care hierarchy, oncology-aware safety, procedural evidence limitations and referral boundaries.
Content review date: 13 July 2026. Treatment suitability and prescribing remain individual clinical decisions.
Educational only. These references are provided for transparency and further reading. They do not replace individual medical assessment, diagnosis, prescribing or personalised treatment planning.
